News >

PVd Regimen Highlighted as New Standard in Relapsed/Refractory Myeloma

Published: Friday, Jul 13, 2018

 Paul Richardson, MD
Paul Richardson, MD
Findings from the phase III OPTIMISMM trial established the combination of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) as a new standard of care in patients with relapsed/refractory multiple myeloma with prior exposure to lenalidomide (Revlimid), said Paul Richardson, MD.

, Richardson discussed the combination’s efficacy and tolerability, as well as the possibility of pairing PVd with other agents to boost outcomes without increasing toxicity in multiple myeloma.

OncLive: Can you discuss the background of this study?

Richardson: We have demonstrated that there is synergy between immunomodulatory (IMiD) treatments and proteasome inhibitors. That's been a paradigm in myeloma treatment for some time.

We randomized about 570 patients across a large number of centers. It was a real global effort—there was a fantastic world partnership with colleagues in Europe, Canada, the United States, and all over the world.

What did you find when you looked at PFS?

What we saw, first and foremost, is that in fact, the PFS benefit with the 3 drugs over the 2 was quite striking and quite early.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication